目的：探讨舒利迭治疗中重度慢性阻塞性肺疾病（COPD）对患者肺部功能、炎症状况改善以及临床治疗效果。方法：选取2015年12月~2016年12月在我院接受治疗的中重度COPD患者70例，根据不同治疗方法将患者分为两组，每组35例，两组患者均给予常规治疗，对照组在此基础上给予茶碱缓释片治疗，观察组给予舒利迭治疗，观察两组患者治疗前、治疗后肺部功能、炎症因子水平表达以、呼吸困难评分变化情况，记录患者治疗后的临床疗效、不良反应，并进行对比分析。结果：治疗后，患者的FEV1、FVC以及FEV1/FVC等肺部功能指标均有提高，两组对比差异具有统计学意义；对比患者治疗前的炎症因子水平表达，无统计学意义，治疗后，患者IL-6、CRP以及TNF-α等血清炎症因子水平表达均有降低，观察组低于对照组，差异显著；经治疗，患者的的呼吸困难评分均低于治疗前，观察组（1.56±0.32）分低于对照组（1.98±0.42）分，差异显著；观察组治疗后的总有效率为94.29%高于对照组71.43%，差异显著；观察组不良反应5.71%低于对照组22.86%，差异显著。结论：给予中重度COPD患者舒利迭治疗，可改善患者的肺部功能，减轻呼吸困难症状，抑制炎症因子表达，效果显著。

Objective To investigate the Seretide in the treatment of moderate and severe COPD (Chronic obstructive pulmonary disease) to improve lung function in patients with you, inflammation status and clinical therapeutic effect. Methods 70 cases of patients with severe COPD from December 2015 to December 2016 in our hospital, according to the different treatment methods were divided into two groups, 35 cases in each group, two groups of patients were given conventional treatment, the control group was given the treatment of Theophylline Sustained-release Tablets, on the basis of the observation group patients were given Seretide treatment, observe two groups of patients before and after treatment, lung function, inflammatory factors expression, dyspnea score the changes recorded in patients with clinical efficacy after treatment, and compared. Results After treatment, the pulmonary function indexes such as FEV1, FVC and FEV1/FVC were improved, and the difference between the two groups was statistically significant; the expression levels of inflammatory factors in the treatment of patients before the comparison, no statistically significant; after the treatment, the expression level of serum inflammatory factors in patients with IL-6, CRP and TNF- etc were decreased, the observation group than the control group, the difference was significant after treatment; , dyspnea score of patients were lower than those before treatment, the observation group (1.56+0.32) lower than that of control group (1.98 + 0.42), significant difference; after treatment, the total effective rate was 94.29% higher than 71.43% in the control group, significant difference the adverse reactions of the observation group was 5.71%, which was lower than that of the control group (22.86%), and the difference was significant. Conclusion Given the severe Seretide treatment in patients with COPD, can improve the patient’s lung function, relieve the symptoms of breathing difficulties, inhibit the expression of inflammatory cytokines, significant effect.